FGFR1 and neoplasm: Anlotinib is a novel oral anti-angiogenic TKI that blocking vascular endothelial growth factor receptor (VEGFR)1-3, fibroblast growth factor receptor (FGFR)1-4, platelet-derived growth factor (PDGFR)-α, PDGFR-β, and stem cell factor receptors, which inhibit tumor angiogenesis and tumor cell proliferation (25, 26).